Advertisement
Canada markets open in 2 hours 12 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7324
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    84.09
    +0.52 (+0.62%)
     
  • Bitcoin CAD

    87,614.49
    +668.33 (+0.77%)
     
  • CMC Crypto 200

    1,383.58
    -12.96 (-0.93%)
     
  • GOLD FUTURES

    2,359.70
    +17.20 (+0.73%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,747.00
    +179.50 (+1.02%)
     
  • VOLATILITY

    15.62
    +0.25 (+1.63%)
     
  • FTSE

    8,117.29
    +38.43 (+0.48%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6821
    0.0000 (0.00%)
     

Myriad Genetics to Participate in BofA Securities Healthcare Conference

Myriad Genetics, Inc.
Myriad Genetics, Inc.

SALT LAKE CITY, May 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will be participating in the upcoming BofA Securities Healthcare Conference in Las Vegas, NV.

Myriad management will participate in a fireside chat on Tuesday, May 9 at 3:00 p.m. PT. A live and archived webcast of the presentation can be viewed in the investor relations section of Myriad’s website at www.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Media Contact:
Glenn Farrell
(385) 318-3718
PR@myriad.com

Investor Contact:
Matt Scalo
(801) 584-3532
IR@myriad.com